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In this report we discuss two cases of patients with Pulmonary Arterial Hypertension. Both patients were
evaluated and were recommended therapy according to current acceptable guidelines. Despite these
recommendations, each patient sought on their own accord, additional therapy in the form of stem cell
therapy. They subsequently received an infusion of stem cells into their pulmonary circulation. Objective
and subjective measures were followed prior to and following infusion. After a review of each case we
brieﬂy discuss the decisions a physician must face when a patient seeks therapies not proven safe or
effective by a governing authority.
 2010 Elsevier Ltd. All rights reserved.1. Introduction
Pulmonary arterial hypertension is characterized by elevated
pulmonary arterial pressure (PAP) and secondary right ventricular
failure, which if left untreated is a life-threatening condition with
a poor prognosis.1 Over the past several years, multiple therapies
have emerged in the management of this disease. The mechanisms
of these agents focus on vasodilation, vascular growth, and
remodeling. However, patients who have pulmonary hypertension
(PH) in association with primary lung disease have a worse prog-
nosis with less well-deﬁned treatment options.2 Over the past
several decades stem cell therapy has been characterized as having
the potential to dramatically change the treatment of human
disease, including PH. In this report, we discuss 2 patients with PH
who were treated by the direct infusion of peripherally harvested
autologous stem cells into the pulmonary arteries. Although these 2
patients were followed by the PH clinic at the Mayo Clinic Florida,
the procedure was not performed at Mayo Clinic. In addition, it was
not performed in the context of an approved clinical trial. These
two patients had independently pursued and obtained this
controversial treatment from Regenocyte Therapeutic at the Centro
Otorrino Laringologia Hospital in Santo Domingo, Dominican
Republic. This report summarizes the clinical experience of both of
these patients from our perspective..
rved.2. Case 1
2.1. Clinical history and course
A 44 year-old Caucasian man and former smoker (38 pack years,
quit 2004) presented for evaluation in December 2006 for symp-
toms of progressive dyspnea (World Health Organization (WHO)
functional class III), fatigue, and presyncopal spells. His past
medical history was signiﬁcant for mild chronic obstructive
pulmonary disease (COPD) and PH diagnosed in 2004, with right
heart catheterization (RHC) revealing a mean pulmonary artery
pressure (MPAP) of 37 mmHg. Additional PH risk factors included
obesity (BMI 33.2), and mild obstructive sleep apnea. The patient
had recently started sildenaﬁl (25 mg dose) on an as needed basis
and reported some reduction in dyspnea after each use.
His laboratory evaluation at our center was normal except for an
elevated hemoglobin (17.7 mg/dL). He was hypoxic on room air (pH
7.4, PaO2 49, PaCO2 33, SaO2 90%), and his pulmonary function test
(PFT) revealed mild obstruction with a reduction in diffusing
capacity for carbon monoxide (DLCO). (Table 1) High-resolution
computed tomography scan of the chest showed diffuse emphy-
sema. The electrocardiogram was normal and the contrast echo-
cardiogram (ECHO) demonstrated mild PH with a right ventricular
systolic pressure (RVSP) of 49 mmHg and MPAP 31 mmHg. There
was mild left-ventricular hypertrophy but right ventricular (RV)
size and function were normal with an estimated right atrial
pressure (RAP) of 5 mmHg. There was no shunt identiﬁed. (Table 2)
A ventilation-perfusion (V/Q) lung scan excluded chronic throm-
boembolic disease (CTED). The patient achieved 519m in the 6-min
walk test (6MWT) performed on 2 L per minute (lpm) oxygen with
a nadir saturation of 84%. Overnight oximetry on room air
Table 1
Pulmonary Function Testing - Pre and Post Stem Cell Infusion.
Date PFT Results
FEV1 FEV1/FVC TLC RV DLCO
Case 1
Dec-06 3.31 L (73%*) 73 6.68 L (89%) 2.06(119%) 16.3 (49%)
Sep-08 3.13 L (71%) 71 6.98 L (95%) 2.26(127%) 16.3 (50%)
Case 2
Oct-07 1.32 L (54%) 44 6.5 L (111%) 3.6 L (138%) 11.8 (64%)
Jul-09 1.33 L (55%) 39 6.8 L (115% 3.4 L (132%) 11.3 (62%
STEM CELL INFUSION 3-08 FEV1 e Forced Expiratory Volume in One Second, FVC e
Forced Vital Capacity, TLC e Total Lung Capacity, RV e Residual Volume, DLCO e
Diffusing Capacity of Carbon Monoxide.
* Percent Predicted.
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signiﬁcant sleep-disordered breathing.
The patient underwent a repeat RHC with cardiopulmonary
exercise testing (CPX). The RHC revealed mild PH at rest that
worsened signiﬁcantly with exercise (MPAP increased from 30 to
58mmHg). (Table 3) Themaximal oxygen consumptionwas 15.7ml
O2/kg/min with an inadequate increase in stroke volume with
exercise. Pulmonary arterial vasodilator trial revealed no signiﬁcant
response to intravenous epoprostenol.
His PH was classiﬁed as WHO diagnostic group 33; therefore,
regular use of adequate oxygen was recommended. He also started
tiotropium inhaler. In addition he was instructed to take sildenaﬁl
regularly at 20 mg three times daily. Over the next 9 months the
patient reported some improvement; however, he remained
dyspneic with minimal exertion. Objective measures of his PH
remained stable (Table 2). Sildenaﬁl use had ceased (Table 4) and he
remained non-compliant with oxygen, using it only at night or when
signiﬁcantly dyspneic. He was evaluated for possible lung trans-
plantation but was not felt to be a good candidate due to noncom-
pliance and his body mass index. The recommendations were for
weight loss and improved compliance with his medical regimen.
In November 2007, he was seen in follow-up and was again
counseled to be more compliant with oxygen and to restart silde-
naﬁl at 20 mg three times daily. The patient had been seen by
a cardiologist outside our institution for intermittent chest pain and
palpitations and had been initiated on diltiazem 180 mg daily.
After exploring alternative therapies at a private facility, the
patient had blood collected for possible stem cell therapy. On
March 4, 2008 he traveled to the Dominican Republic where heTable 2
Case 1 e Cardiopulmonary Data.
6 Minute walk
DATE BMI BNP WHO functional class Distance (meters) Sa02(%)/
FIO2 (L)
Borg
Dec-06 33.2 20 3 530 84/8 1
Apr-07 34.9 25 3 550 88/6 3
Oct-07 32.9 17 3 470 91/10 3
Nov-07 34.0 31 2 596 88/10 3
Feb-08 34.3 54 3 512 91/10 2
Mar-08 STEM CELL INFUSION
May-08 35.2 26 2 556 91/8 1
Nov-08 37.2 16 3 580 86/8 3
Feb-09 37.1 39 3 600 93/15 4
May-09 37.1 57 3 619 90/10 3
Mar 10 35.8 19 3 586 92/15 5
BMIe BodyMass Index, BNPe Brain Natriuretic Peptide,WHOeWorld Health Organizati
Pressure, TR e Tricuspid Regurgitant (peak), RVSP e Right Ventricular Systolic Pressure,
describe degree of enlargement and ventricular dysfunction.
* Unable to estimate due to incomplete tricuspid regurgitant jet.received multiple infusions, of what was reported to be the har-
vested stem cells, directly into the pulmonary arteries.
Shortly after the infusion, he reported feeling like “Superman,”
running 1e2 h in the ﬁrst few days. By his report, his room air
saturations rose to 99% at 2 weeks, but deteriorated subsequently.
Other perceived beneﬁts included decreased fatigue, chest pain,
palpitations, and leg pain and even improved vision and mental
acuity. His symptomatic improvements persisted at subsequent
visits despite becoming more sedentary and gaining 4.5 kg.
Notably, he had become more compliant with the use of oxygen to
about 3 lpm by nasal cannula at rest.
Objectively, there were also improvements noted in his 6MWT
and in the echocardiographic estimates of his pulmonary pressures.
(Table 2) These improvements were sustained at repeated follow-
ups. However, the oxygen requirement remained 8 to 15 lpm with
exertion.
At his most recent visit in March 2010, the patient reported that
many of the initial subjective improvements had waned. Overall his
objective measures remained relatively stable. (Table 2) He had
a repeat RHC demonstrating mild resting but severe exercise
induced PH. (Table 3) He is considering a second infusion of stem
cells in the future.3. Case 2
3.1. Clinical history and course
A 78 year-old Caucasian man presented with dyspnea on exer-
tion (WHO functional class II). He had smoked cigars for 19 years
and quit 20 years ago. He was diagnosed with moderate COPD and
was treated with inhaled bronchodilators. A few months prior to
his presentation at Mayo Clinic, an extensive evaluation including
an RHC, a V/Q scan and a pulmonary arteriogram demonstrated PH
due to CTED. Those studies were reviewed and felt to be conclusive.
His medications included hydrochlorothiazide, furosemide, and
warfarin. A PFT demonstrated moderate obstruction, air trapping,
a reduced DLCO, and oxygen desaturation with exercise. (Table 1)
The 6MWT and ECHO results are reported in Table 5. Arterial blood
gas on room air was: pH 7.47, PaO2 67, PaCO2 37; and the BNP was
178 pg/mL. Cardiac MRI revealed RV enlargement and hypertrophy
with a reduced RV ejection fraction to 27%. A repeat RHC was
performed, and it was felt the PH was multi-factorial secondary to
COPD, CTED, and mild pulmonary venous hypertension. (Table 3)
Given the patient’s age, minimal symptoms, multiple mechanismsEcho data
dyspnea score RAP TR jet velocity RVSP MPAP RV Size RV Function
5 3.3 49 31 Normal Normal
5 3.5 54 45 Mild Normal
10 3.5 59 43 Normal Normal
5 3.6 57 Mild Normal
5 3.6 57 41 Normal Normal
5 3.1 43 28 Normal Normal
5 3.2 46 33 Normal Normal
5 3.3 49 29 Mild Normal
5 3.2 46 N/A* Mild Normal\
5 3.3 49 36 Normal Normal
on, Sa02eOxygen Saturation, FIO2e Fraction of Inspired Oxygen, RAPe Right Atrial
MPAP e Mean Pulmonary Artery Pressure, RV e Right Ventricle, Normal and Mild
Table 3
Baseline and Post Stem Cell Tranfusion Right Heart Catheter Data.
RAP
(mmHG)
PAP
(mmHG)
MPAP
(mmHg)
PAOP
(mmHg)
CO/CI
(L/min, L/min/m2)
PVR
(dyn s cm-5)
Vasodilator
Response
MPAP During
Exercise (mmHg)
Case 1 Baseline 1/2007 4 45/25 30 12 5.1/2.1 282 No 58
Follow-up
3/2010
6 44/20 28 14 8.3/3.3 135 No 70
Case 2 Baseline
10/2007
11 85/34 51 16 5.8/3.2 478 No N/A *
Follow-up NOT PERFORMED
RAP e Right Atrial Pressure, PAP e Pulmonary Artery Pressure, MPAP eMean Pulmonary Artery Pressure, PAOP e Pulmonary Artery Occlusion Pressure, CO e Cardiac Output,
CI e Cardiac Index, PVR e Pulmonary Vascular Resistance.
* Exercise study not performed.
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pulmonary endarterectomy, and the patient elected for conserva-
tive therapy. An inferior vena cava ﬁlter was placed and life-long
anti-coagulation was recommended. In addition, supplemental
oxygen with exercise and sildenaﬁl 20 mg three times daily were
initiated (Table 4).
Six-months later, there was a slight improvement in the 6MWT
(Table 5). He was now requiring increasing oxygen to maintain
saturations at rest (1.5 lpm) and during exertion. Given persistently
elevated right-heart pressures and RV enlargement and hypo-
kinesis, bosentan was added to his regimen. Eight months after
adding bosentan, he continued to show improvement in the 6MWT
but the ECHOwas unchanged. Oxygen needs continued to increase,
now requiring 2 lpm at rest and 15 lpm for the 6MWT (Table 5).
Three months later, he underwent adult stem infusion. This date
corresponded to 18 months on sildenaﬁl 20 mg three times daily
and 12months on bosentan at full dose. Oneweek after the harvest,
he traveled to Santo Domingo for the infusion into his pulmonary
arteries via a pulmonary artery catheter at Centro Otorrino Lar-
ingologia Hospital. Repeat ECHO one month later showed an RVSP
of 55 mmHg which was exactly the same as his baseline value one
month prior to the infusion. Another ECHO performed by Rege-
nocyte Therapeutics three months after the stem cell infusionTable 4
PH Medications.
Date PAH Medications Oxygen use
Case 1 e Medication and Oxygen Use
Dec-06 Sildenaﬁl 25 mg
(Non-compliant)
3 L NC when symptomatic
Apr-07 None 3 L NC when symptomatic
Oct-07 Sildenaﬁl 25 mg TID
(Non-compliant)
QHS/PRN 3 L NC
Nov-07 Sildenaﬁl 25 mg TID
(Non-compliant)
QHS/PRN 3 L NC
Feb-08 Sildenaﬁl 20 mg TID
Diltiazem 180 mg QD
QHS/PRN 3 L NC
Mar-08 STEM CELL INFUSION STEM CELL INFUSION
May-08 Sildenaﬁl 20 mg TID
Diltiazem 180 mg QD
PRN 3 L NC
Nov-08 Sildenaﬁl 20 mg TID PRN 3 L NC
Feb-09 Sildenaﬁl 20 mg TID 2-3 L NC at rest
May-09 Sildenaﬁl 20 mg TID 2-3 L NC at rest
Case 2 e Medication and Oxygen Use
Aug-07 None None
Apr-08 Sildenaﬁl 20 mg TID 1.5 L NC
Dec-08 Sildenaﬁl 20 mg TID Bosentan
125 mg BID
3.0 L NC
Mar-09 STEM CELL INFUSION STEM CELL INFUSION
Aug-09 Sildenaﬁl 20 mg TID, Bosentan
125 mg BID
3.0 L NC
PAH e Pulmonary Arterial Hypertension, NC e Nasal Cannula, BID e Twice Daily,
TID e Three Times Daily, QD e Daily, QHS e Nightly, PRN e As Needed.demonstrated an RVSP 41 mmHg. A PFT four months after stem cell
infusion was essentially unchanged (Table 1).
The patient was seen in follow-up at Mayo Clinic approximately
5 and 12 months after his stem cell infusion. He stated that he felt
neither better nor worse after his stem cell treatment and was on
3 lpm oxygen to maintain an adequate resting saturation. His
objective assessment showed some beneﬁt at 5 months. (Table 5)
That beneﬁt had waned one year after stem cell infusion. His
treatment regimen included diuretics, warfarin, sildenaﬁl 20 mg
three times daily, bosentan 125 mg twice daily and oxygen. He has
also been regularly participating in a formal pulmonary rehabili-
tation program. No changes were made in his medical regimen.
4. Discussion
Use of stem cell therapy for the treatment of PH is gaining
increasing attention. In the past decade, circulating bone mar-
rowederived cells similar to embryonal angioblasts have been
identiﬁed,4 termed “endothelial progenitor cells (EPC).” These cells
have the potential to proliferate and differentiate into mature
endothelial cells. Two major types of these cells in human periph-
eral blood have been termed “early EPC’s” and “late outgrowth
EPC’s,” both ofwhich appear to have potential in lungmicrovascular
repair and restoring vascular structures of the lung.5
A number of trials are currently underway to evaluate the safety
and effectiveness of the infusion of stem cells. A pilot trial of
autologous EPC administration for idiopathic pulmonary arterial
hypertension was conducted at Zhejiang University, Hangzhou,
China. The trial was a 12-week follow-up of patients after systemic
administration of autologous EPC’s plus conventional therapy
compared with patients receiving conventional therapy alone.6 The
results included increased 6-min-walk capacity and improved
hemodynamic variables, including MPAP, pulmonary vascular
resistance, and cardiac output. No concerns with the safety of the
administration of EPC’s were encountered. The Pulmonary Hyper-
tension and Cell Therapy (PHACeT) trial by the University of Tor-
onto reported on the administration of autologous EPCs transduced
to express eNOS. Three patients in their initial panel showed
a remarkable (nearly 50%) reduction in total pulmonary vascular
resistance over the course of the 3-day delivery period. Subsequent
study in additional patients is currently underway.7
In our report, we present two patients who had peripherally
harvested autologous stem cells infused into the pulmonary
arteries. The procedure was not performed at Mayo Clinic. In
addition, it was not endorsed by Mayo Clinic nor was it performed
in the context of an approved clinical trial. The procedures were
performed by Regenocyte Therapeutic. The reported infusion
occurred at the Centro Otorrino Laringologia Hospital in Santo
Domingo, Dominican Republic. Neither of our patients had idio-
pathic pulmonary arterial hypertension. Each patient was on
concomitant therapy at the time of the stem cell infusion which
Table 5
Case 2 e Cardiopulmonary Data.
6 Minute walk echo data
DATE BMI BNP WHO functional class Distance (meters) Sa02(%)/FIO2 (L) Borg dyspnea score RAP TR jet velocity RVSP MPAP RV Size RV Function
Aug-07 28.1 178 2 291 91/4 5 5 4.3 79 47 Moderate Moderate
Apr-08 28.0 119 2 339 89/15 5 5 4.3 79 47 Moderate Moderate
Dec-08 28.4 38 2 384 90/15 4 15 4.0 79 58 Moderate Moderate
Mar-09 STEM CELL INFUSION
Aug-09 28.3 40 2 401 94/15 3 N/A* N/A* N/A* N/A* Mild Normal
May-10 28.4 87 3 373 96/15 4 16 4.0 80 58 Mod/Sev Mod/Sev
BMIe BodyMass Index, BNPe Brain Natriuretic Peptide,WHOeWorld Health Organization, Sa02eOxygen Saturation, FIO2e Fraction of Inspired Oxygen, RAPe Right Atrial
Pressure, TR e Tricuspid Regurgitant (peak), RVSP e Right Ventricular Systolic Pressure, MPAP e Mean Pulmonary Artery Pressure, RV e Right Ventricle; Normal,Mild and
Moderate describe degree of enlargement and ventricular dysfunction.
* Unable to estimate due to incomplete tricuspid regurgitant jet.
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tions. Case 1 had a dramatic positive response as reported subjec-
tively by the patient. At the time of follow-up many of these
improvements had waned, however the patient was found to have
improvement in both his resting pulmonary pressures by ECHO and
6MWT. (Table 2) These reductions in MPAP appeared to be sus-
tained up to 24 months post infusion. Unfortunately, these func-
tional and hemodynamic improvements did not translate into any
signiﬁcant change in the severe hypoxemia. Case 2 did not have any
change in his symptoms or WHO functional class. He continued to
have increasing supplemental oxygen requirements. His 6-min
walk distance had slightly improved, and his ECHO demonstrated
improved right ventricular function.
Are any of the changes due to the stem cell infusion? It is
impossible to determine in an uncontrolled setting. The role of
multiple ongoing therapies and the limitations of the clinical
assessments are particularly challenging to evaluate. Both
patients were on multiple therapies for PH at the time they
received the stem cell infusion. Variations in oxygen require-
ments and supplementation may be particularly confounding
since both patients had signiﬁcant COPD. Although validated
surrogate endpoints in assessing response to therapy remain
a source of ongoing discussion, both WHO functional class and
6MWT have been used to monitor disease course and gauge
response to therapy.8,9 Case 1 seemed to have improvement in
both WHO functional class and 6MWT while Case 2 had no
change in symptoms and a modest 17 m walk improvement. Only
Case 1 had an RHC subsequent to the stem cell transfusion. There
was no signiﬁcant change compared to baseline. The clinical
evaluations in Case 2 were limited to non-invasive measures.
Echocardiography has been used as a surrogate to evaluate right
heart pressures and function and was the only assessment
available in Case 2. Measurement of MPAP by ECHO has been
demonstrated to closely track that measured by RHC in a pop-
ulation of patients.10
If there were some beneﬁt, it is unfortunate that it will remain
inconclusive. Case 1 had subjective improvement; however, his
clinical scenario was complex as outlined above. These cases
present several challenging dilemmas for the clinician in this
evolving area of science. Prior to the stem cell transplantation, we
were struggling with the best treatment approach in each case. In
Case 1, we informed the patient that the only proven therapy for
COPD in the setting of hypoxia was oxygen therapy.11,12 Nonethe-
less, he had difﬁculties with compliance. In addition, he felt
subjectively improved on the sildenaﬁl, started before presenting
to our center and we documented signiﬁcant worsening in his
MPAPwith exercise. In light of the evidence that sildenaﬁl had little
downside in the setting of hypoxia,13 we elected a trial, explaining
to the patient that the therapy was unproven. Case 2 had multiplereasons for PH but predominantly CTED. He was considered for
pulmonary endarterectomy but was felt to be high risk and he
deferred. Again, there are no proven medical therapies but some
evidence in favor of treatment with sildenaﬁl and bosentan.14,15
Other than modest improvements and potentially slowing the
progression of disease, the oral pulmonary vasodilators likely had
little clinical beneﬁt in either case.
The stem cell transplant raised the issue of unproven therapies
to a new level as the patients personally paid approximately
$50,000 for the therapy that was administered outside the context
of either a clinical or research setting. In addition, the therapy was
pursued independently of our clinical recommendation or over-
sight. Also of interest in these particular cases, was the potential
impact on the relationship between the physician and patient since
the patients had pursued an unendorsed experimental therapy
outside the country. Although our stance on the experimental
nature of stem cell therapy for PH has always been clear, both of
these patients researched, pursued and ﬁnanced the therapy on
their own accord. The clinician must be prepared for any potential
conﬂict that may ensue if the patient seeks an experimental,
unapproved therapy. In our practice, wemaintain that such therapy
should only be administered in the context of an approved research
protocol, however continue to treat the patient regardless of the
decisions they make.5. Conclusion
Stem cell therapy has emerged as a safe and promising means to
potentially treat a number of diseases, including pulmonary
hypertension. Current ongoing safety and efﬁcacy trials will likely
add signiﬁcantly to our current understanding of the ﬁeld, with
hopes of aiding in future patient care. In a parallel fashion, patients
are pursuing this form of therapy outside of controlled research
trials. Such practices create signiﬁcant challenges in evaluating
efﬁcacy and potentially stress the provider-patient relationship in
unique ways.
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